The VSee Health, Inc. (NASDAQ: VSEE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a telehealth technology and services company in the health information services sector, VSee uses its filings to report on business operations, capital structure, financing arrangements, and Nasdaq listing matters.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for information on VSee’s healthcare technology and telehealth services segments, revenue composition, costs, and risk factors. These core filings outline how the company describes its AI-powered telehealth platform, high-acuity virtual care services, and digital health offerings that integrate secure video, device data, and EHR connectivity for hospital systems, health networks, employers, and enterprise partners.
VSee’s current reports on Form 8-K document material events such as private placements of common stock and warrants, convertible note agreements, warrant exchanges, equity line of credit arrangements, and amendments tied to Nasdaq stockholders’ equity requirements. Recent 8-K and 8-K/A filings describe steps the company has taken to address Nasdaq Listing Rule 5550(b)(1), including capital transactions and conversions of outstanding instruments, as well as governance items like annual meeting scheduling and bylaw amendments affecting quorum.
Through this page, users can also locate proxy materials on Schedule 14A, which detail proposals for director elections, auditor ratification, equity incentive plans, and adjournment authority, along with information on voting rights for common and preferred stock. For those monitoring ownership and compensation, insider transactions and related disclosures can be reviewed via the relevant SEC forms where available.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand complex capital structures, financing terms, and operational disclosures without replacing the full text of the official filings.
VSee Health, Inc. registered up to 3,540,000 common shares for resale by ClearThink Capital Partners, LLC: 40,000 commitment-fee shares already issued and up to 3,500,000 shares VSee may issue and sell to ClearThink under the Strata Agreement. VSee receives no proceeds from ClearThink’s resales, but may receive proceeds from separate sales to ClearThink; ClearThink committed to purchase up to $5.0 million of shares, subject to the agreement’s conditions.
Under the Strata Agreement, VSee may direct purchases over an approximately 36-month period beginning after the resale registration statement is declared effective and remains effective, subject to the agreement’s conditions. The purchase price is 85% of the lowest daily closing price during the 10 trading days preceding the purchase date. VSee may not direct purchases that would put ClearThink and its affiliates’ beneficial ownership above 9.99% of outstanding common stock. VSee expects any proceeds from its sales to be used for working capital and general corporate purposes.
The auditor identified material weaknesses in financial reporting controls for the year ended December 31, 2025. Management concluded substantial doubt exists about VSee’s ability to continue as a going concern for one year after the financial statements were issued. Operating cash outflows were $3,625,916 for the six months ended June 30, 2026.
VSee Health, Inc. issued Vanquish an additional unsecured convertible promissory note with an aggregate principal amount of $180,550 on September 24, 2026; the amount includes a $23,550 original issue discount. The note carries a one-time 12% interest charge applied to principal on issuance and is due July 30, 2027. It may be prepaid in whole or in part at any time without penalty.
Vanquish may convert only upon the occurrence and during the continuance of an Event of Default. The conversion price is 65% of the lowest closing bid price over the 10 trading days before written notice, subject to specified equitable adjustments; conversion cannot result in Vanquish and its affiliates owning more than 4.99% of VSee Health’s outstanding common stock, and that limit cannot be waived. VSee Health may accelerate payments or prepay in cash for a certain percentage of principal then outstanding plus accrued and unpaid interest, based on the prepayment date. The June 18, 2026 agreement permits additional financings up to $2,050,000 during the 12 months after that date, subject to further agreement.
VSEE HEALTH, INC. (symbol: VSEE) is the issuer of record for a Form 8-K filing submitted to the SEC.
VSee Health, Inc. (VSEE) entered into a Strata Purchase Agreement with Clearthink Capital Partners, LLC on September 2, 2026, under which Clearthink committed to purchase up to $5.0 million of VSee common stock at VSee’s direction, subject to conditions and effectiveness of a resale registration statement.
VSee may issue Request Notices over an approximately 36‑month period, with each draw limited to the lesser of $1,000,000 or 300% of the average trading volume over the prior eight trading days. The purchase price per share will be 85% of the lowest daily closing price during the ten trading days before each purchase date. Clearthink cannot demand sales and is capped at 9.99% beneficial ownership of VSee’s outstanding common stock.
As consideration for Clearthink’s commitment, VSee agreed to issue 40,000 shares of common stock as Commitment Fee Shares, deemed earned upon signing. The company states that any proceeds from sales under this facility are expected to be used for working capital and general corporate purposes, relying on Section 4(a)(2) and Regulation D exemptions.
VSee Health, Inc. (VSEE) reported that on August 27, 2026, Scott Metzger resigned, effective immediately, from its Board of Directors and from the Board’s Compensation Committee. The company states that Mr. Metzger’s resignation is not due to any disagreement regarding operations, policies, or practices.
The company’s common stock has a par value of $0.0001 per share and trades under the symbol VSEE, with warrants trading as VSEEW, each entitling the holder to purchase one share of common stock at $11.50 per whole share.
VSEE HEALTH, INC. (VSEE) reported the results of its August 25, 2026 annual meeting of stockholders. Common stock outstanding as of the July 6, 2026 record date was 55,679,813 shares, and 121.698 shares of preferred stock were outstanding; holders representing 50.65% of combined voting power were present, constituting a quorum.
Stockholders elected Kevin Lowdermilk and Colin O’Sullivan as directors until the 2029 annual meeting. They also ratified WWC, P.C. as independent registered public accounting firm for the year ending December 31, 2026. In addition, stockholders approved giving the board discretionary authority to implement one or more Reverse Stock Splits of the common stock within a range of 1-for-20 up to 1-for-80, provided aggregate splits do not exceed 1-for-80 and any reverse split is completed no later than the second anniversary of the record date. An adjournment proposal related to these items was also approved.
VSee Health, Inc. operates a telehealth services business centered on iDoc and reports continued losses and liquidity pressure for the quarter ended June 30, 2026. From continuing operations, revenue rose to $1.56 million for the quarter and $3.44 million for the first six months of 2026, up from $1.06 million and $2.25 million in the prior-year periods, but gross margin compressed and operating expenses increased, leading to a six‑month loss from continuing operations of $4.34 million.
Including discontinued operations, the company recorded net income driven by the May 31, 2026 divestiture of VSee Lab to former co‑CEO Milton Chen, recognizing a $4.17 million gain and cancelling 2,870,069 common shares. Cash fell sharply to $454,151 from $5.05 million at year‑end, with $2.50 million of operating cash outflows from continuing operations in the first half. Total assets were $16.73 million and total liabilities $9.14 million, leaving equity of $7.59 million. Management states that recurring losses, an accumulated deficit of $84.17 million, and limited liquidity raise substantial doubt about the company’s ability to continue as a going concern, despite past funding through debt and equity and ongoing efforts to improve its position.
VSee Health, Inc. has received an updated ownership report showing that Armistice Capital, LLC and Steven Boyd, together defined as the Reporting Persons, beneficially own 4,079,129 shares of VSee Health common stock. This represents 7.33% of the outstanding common stock.
The Reporting Persons report no sole voting or dispositive power over these shares and instead have shared voting and shared dispositive power over all 4,079,129 shares. The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager under an Investment Management Agreement. Armistice Capital and Mr. Boyd may be deemed to beneficially own these securities, while the Master Fund has the right to receive dividends and sale proceeds.
VSee Health, Inc. reported that Nasdaq’s Listing Qualifications Staff has issued a Staff Delisting Determination after its securities had a closing bid price of $0.10 or less for ten consecutive trading days during an existing bid-price compliance period. The company had previously received notice of noncompliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum $1.00 bid price, and was given until March 27, 2026, later extended to September 21, 2026, to regain compliance.
Nasdaq has determined to delist VSee Health’s common stock and warrants from the Nasdaq Capital Market, and trading will be suspended at the opening on August 6, 2026, with a Form 25-NSE to remove the securities from listing and registration. VSee Health may request a hearing before the Nasdaq Hearings Panel by 4:00 p.m. Eastern Time on August 6, 2026, with a non-refundable $20,000 fee, but the company notes there is no assurance of success and a timely hearing request will not stay the trading suspension.
On June 30, 2026, VSee Health, Inc. entered into a securities purchase agreement with an institutional investor, issuing an unsecured convertible promissory note (the Labrys Note) with aggregate principal of $336,000, including an original issue discount of $36,000 and a one-time 12% interest charge, due June 30, 2027.
The investor may require up to 50% of future cash proceeds from specified sources to repay the note. After certain timing and registration conditions, the note is convertible into common stock at 75% of the lowest closing bid price over the 10 trading days before conversion, subject to a 4.99% beneficial ownership cap. The securities were issued in a private placement exempt from registration under Section 4(a)(2) and Regulation D.